Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07002801
Active, not recruiting Not applicable

Application of Remimazolam Combined With Esketamine in Painless Gastroscopy and Colonoscopy in Elderly Patients

NCT07002801 · tracked via the Priya Life Science China tracker
Sponsor
Harbin Medical University
Phase
Not applicable
Started
2025-05-14
Last updated
2026-10-19

Condition(s) studied

Gastrointestinal Disease

Investigational drug(s) / intervention(s)

remimazolam-remifentanilremimazolam-esketamine

remimazolam-remifentanil: For elderly patients scheduled for elective painless gastro-intestinal endoscopy, remimazolam 0.2mg/kg and remifentanil 0.2ug/kg are used for anesthesia induction. During the operation, the doses are adjusted according to the depth of sedation of the patients.

remimazolam-esketamine: For elderly patients scheduled for painless gastroenterological endoscopy, remimazolam 0.2mg/kg and esketamine 0.15mg/kg are used for anesthesia induction. During the operation, the dosage is adjusted according to the patient's level of sedation.

Study summary

The objective of this clinical trial is to assess the feasibility of the remimazolam combined with esketamine OFA (opioid-free anesthesia) protocol for painless gastroscopy and colonoscopy in elderly patients and to determine if it is non-inferior to the traditional OA (opioid-containing anesthesia) protocol. The main questions it aims to answer are:

* Is the remimazolam combined with esketamine protocol feasible for painless gastroscopy and colonoscopy in elderly patients?
* Is the OFA protocol superior to the OA protocol?

Participants will:

* During anesthesia induction, the experimental group will receive remimazolam combined with esketamine for anesthesia, while the control group will receive remimazolam combined with remifentanil.
* Record respiratory and circulatory indicators and adverse reaction times.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients undergoing painless gastroenteroscopy in outpatient clinics; 2. aged 65 years and above; 3. American Society of Anesthesiologists (ASA) grades I - III. Exclusion Criteria: 1. Patients with abnormal liver or kidney function; 2. known respiratory or endocrine diseases; 3. Patients with uncontrolled hypertension and NYHA classification Ⅲ-Ⅳ; 4. Taking monoamine oxidase inhibitors, sedatives, analgesics, hypnotics, antipsychotics, antiemetics or antidepressants; 5. Addiction to tobacco and alcohol; 6. Patients allergic to the investigational drug; 7. expected difficult airway; 8. Body mass index (BMI) \>35kg/m\^2; 9. Have participated in other clinical trials within the past three months; 10. Patients with psychosocial illness or cognitive dysfunction and inability to cooperate or communicate.

Primary outcome measure(s)

  • Sedation success rate — From the start of anesthesia induction to the end of the surgery
    Successful sedation：① The patient underwent painless gastroenteroscopy;②During anesthesia induction, a single remazolam is not enough to achieve sufficient sedation depth, and it needs to be remedied, and the number of remediations within 15min is less than 5 times; Intraoperative supplementary times ≤5 times within any 15min.③ The patient did not use rescue drugs;Sedation success rate: Number of patients successfully sedated/total number of patients included in the data analysis for this group
  • Incidence of hypotension — From the start of anesthesia induction to the end of the surgery
    Hypotension: systolic blood pressure below 80% of baseline systolic blood pressure or MAP below 80% of baseline MAP; Incidence of hypotension: Number of patients with intraoperative hypotension/total number of patients included in the data analysis for this group

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Harbin Medical University Harbin Heilongjiang

More Harbin Medical University trials in China

Study on the Improvement of Myocardial Microcirculation After Acute Anterior Myocardial Infarction Recruiting
Constructing a Risk Prediction Model for Intraoperative Hypothermia in Children Under General Anesthesia Enrolling by invitation
Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy Active, not recruiting
Cardiovascular Risk Early Screening and Warning in Harbin : A Prospective Cohort Study Starting soon
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07002801 on ClinicalTrials.gov ↗ ← All trials in China